Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.
According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.
ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA